Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283648 | 1.00 | ADRB3 (0.38) | ADRB3KMOFFAR4KCNA5KDM4D | |
| SCHEMBL7090210 | 0.93 | ADRB3 (0.34) | ADRB3FFAR4KCNA5KDM4DGPR119 | |
| SCHEMBL6282469 | 0.93 | ADRB3 (0.34) | ADRB3FFAR4KCNA5KDM4DGPR119 | |
| SCHEMBL6284029 | 0.90 | FFAR4 (0.35) | ADRB3FFAR4KDM4DGPR119FFAR1 | |
| SCHEMBL6284018 | 0.90 | FFAR4 (0.35) | ADRB3FFAR4KDM4DGPR119FFAR1 | |
| SCHEMBL6280603 | 0.86 | KDM4D (0.34) | ADRB3FFAR4KDM4DGPR119FFAR1 | |
| SCHEMBL6280608 | 0.86 | KDM4D (0.34) | ADRB3FFAR4KDM4DGPR119FFAR1 | |
| SCHEMBL6287396 | 0.85 | FFAR4 (0.35) | ADRB3FFAR4GPR119ROCK2FFAR1 | |
| SCHEMBL6287391 | 0.85 | FFAR4 (0.35) | ADRB3FFAR4GPR119ROCK2FFAR1 | |
| SCHEMBL6784959 | 0.83 | GPR119 (0.35) | ADRB3FFAR4GPR119FFAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-6919371-B2 | 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
| EP-0282944-B1 | Pyrazole derivative and herbicide containing it | NISSAN CHEMICAL IND LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5175299-A | Benzoic acid derivatives useful as intermediates for the preparation of herbicidal 4-benzoylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| US-4948887-A | FOR UPLAND FIELDS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4885022-A | Herbicidal pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-12-05 | — | — | US | disclosed |
| EP-0282944-A2 | Pyrazole derivative and herbicide containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885KMO 1589/4885FFAR4 332/4885 |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | ADRB3 6/4885KMO 3911/4885FFAR4 1891/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | ADRB3 8/4885KMO 4267/4885FFAR4 2383/4885 |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885KMO 1589/4885FFAR4 332/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885KMO 1589/4885FFAR4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.